Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.

Moyle G, Else L, Jackson A, Back D, Yapa MH, Seymour N, Ringner-Nackter L, Karolia Z, Gazzard B, Boffito M.

Antimicrob Agents Chemother. 2013 Aug;57(8):3640-4. doi: 10.1128/AAC.00357-13. Epub 2013 May 20.

2.

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir.

Pham PA, Flexner C, Parsons T, Vasist L, Fuchs E, Carson K, Agarwala S, Barditch-Crovo P.

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):201-5.

PMID:
17414932
3.

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

Moltó J, Santos JR, Valle M, Miranda C, Miranda J, Blanco A, Negredo E, Clotet B.

Ther Drug Monit. 2007 Oct;29(5):648-51.

PMID:
17898658
4.

Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.

Bertz RJ, Persson A, Chung E, Zhu L, Zhang J, McGrath D, Grasela D.

Pharmacotherapy. 2013 Mar;33(3):284-94. doi: 10.1002/phar.1205.

PMID:
23456732
5.
6.

Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.

Fabbiani M, Di Giambenedetto S, Ragazzoni E, Colafigli M, Prosperi M, Cauda R, Navarra P, De Luca A.

HIV Med. 2010 May;11(5):326-33. doi: 10.1111/j.1468-1293.2009.00785.x. Epub 2010 Dec 9.

7.

Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.

Bunupuradah T, Techasaensiri C, Keadpudsa S, Thammajaruk N, Srimuan A, Sahakijpicharn T, Prasitsuebsai W, Ananworanich J, Puthanakit T; HIV-NAT 146 Study Team..

Pediatr Infect Dis J. 2014 Dec;33(12):e316-9. doi: 10.1097/INF.0000000000000469.

PMID:
24983717
8.

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.

Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study team..

AIDS. 2010 Aug 24;24(13):2019-27. doi: 10.1097/QAD.0b013e32833bee1b.

PMID:
20613461
9.

Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.

Martin DE, Galbraith H, Schettler J, Ellis C, Doto J.

Clin Ther. 2008 Oct;30(10):1794-805. doi: 10.1016/j.clinthera.2008.10.006.

PMID:
19014835
10.

The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.

Zhang J, Chung E, Yones C, Persson A, Mahnke L, Eley T, Xu X, Bertz R.

Antivir Ther. 2011;16(2):157-64. doi: 10.3851/IMP1724.

PMID:
21447864
11.

Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.

Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, Pozniak A, Nelson M, Gazzard B, Back D, Boffito M.

Antivir Ther. 2007;12(5):825-30.

PMID:
17713166
12.

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.

Boffito M, Kurowski M, Kruse G, Hill A, Benzie AA, Nelson MR, Moyle GJ, Gazzard BG, Pozniak AL.

AIDS. 2004 Jun 18;18(9):1291-7.

PMID:
15362661
13.

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.

Burger DM, Agarwala S, Child M, Been-Tiktak A, Wang Y, Bertz R.

Antimicrob Agents Chemother. 2006 Oct;50(10):3336-42.

14.

Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.

Gantner P, Koeppel C, Partisani M, Batard ML, Bernard-Henry C, Cheneau C, De Mautort E, Priester M, Muret P, Sueur C, Fafi-Kremer S, Rey D.

Scand J Infect Dis. 2014 Dec;46(12):838-45. doi: 10.3109/00365548.2014.947318. Epub 2014 Sep 17.

PMID:
25229167
15.

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.

Rodríguez-Nóvoa S, Morello J, Barreiro P, Maida I, García-Gascó P, Vispo E, González-Pardo G, Parra A, Jiménez-Nácher I, Soriano V.

AIDS Res Hum Retroviruses. 2008 Jun;24(6):821-5. doi: 10.1089/aid.2007.0276.

PMID:
18507524
16.

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.

Schipani A, Dickinson L, Boffito M, Austin R, Owen A, Back D, Khoo S, Davies G.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):60-6. doi: 10.1097/QAI.0b013e3182737231.

17.

Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.

Foissac F, Blanche S, Dollfus C, Hirt D, Firtion G, Laurent C, Treluyer JM, Urien S.

Br J Clin Pharmacol. 2011 Dec;72(6):940-7. doi: 10.1111/j.1365-2125.2011.04035.x.

18.

Ritonavir boosting dose reduction from 100 to 50 mg does not change the atazanavir steady-state exposure in healthy volunteers.

Estévez JA, Moltó J, Tuneu L, Cedeño S, Antonijoan RM, Mangues MA, Clotet B, Domingo P, Puntes M, Barbanoj MJ, Valle M.

J Antimicrob Chemother. 2012 Aug;67(8):2013-9. doi: 10.1093/jac/dks152. Epub 2012 May 7.

PMID:
22566588
19.

Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.

Bonora S, Gonzalez de Requena D, D'Avolio A, Calcagno A, Tettoni M, Siccardi M, Baietto L, Simiele M, Trentini L, Di Perri G.

Antivir Ther. 2011;16(4):499-504. doi: 10.3851/IMP1802.

PMID:
21685537
20.

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.

Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL; Adolescent Trials Network for HIV/AIDS Interventions..

Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. Epub 2007 Nov 19.

Supplemental Content

Support Center